Vycor Medical Inc. · OTC:VYCO
Vycor Medical — Investor Presentation (December 2014)
30 slides from Vycor Medical's investor presentation, December 2014
Slide 1: Investor Presentation
Investor Presentation December 2014
Slide 2: Forward-looking statements
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect"
Slide 3: Two distinct businesses with game changing products
• Two distinct businesses – both with “game changing” products • Devices are FDA-cleared, development risk now off the table • Address significant markets – NovaVision ~$4bn in the US/Europe, up to ~$13bn globally – Vycor $700m globally • Limited competition – NovaVision VRT only FDA cleared therapy
Slide 4: NovaVision and ViewSite
NovaVision ViewSite Leader in the field of vision rehabilitation Lead product ViewSite Brain Access System for neurological brain damage e.g. stroke. (VBAS) is a revolutionary neurosurgical Suite of complementary therapies: device used to gain access to a target within • Vision Restoration Therapy (
Slide 5: NovaVision Subsidiary and Vycor Medical
NovaVision Subsidiary ycor Y MEDICAL, Innovative Neurosurgical and Neurotherapeutic Solutions, $83: NovaVision’ a iN Broo, Sguccun” en —— SIGHTSCIENC a NovaVision® company Neur6eiGeach
Slide 6: Suite of Complementary Therapies for Visual Field Deficits
Has a Suite of Complementary Therapies Address Patients with Visual Field Deficits Resulting from Stroke, Brain Injury or Other Neurological Trauma Visible object 6
Slide 7: Significant Target Market
• ~8 million Stroke survivors in US. 480,000+ new stroke survivors a year • 28% of Stroke victims suffer from visual disorders • 20% experience permanent visual field deficits Significant Target Market Est. US/Europe $4bn, Globally up to $13bn 7
Slide 8: Vision Loss from Stroke and TBI is a Big Unaddressed Issue
Vision Loss from Stroke and TBI is a Big Unaddressed Issue • The current pillar therapy areas are: – Speech – Physical Key Therapies – Occupational Occupational Vision • NovaVision focuses on the critical missing therapy Visual Field Deficit is a Major Inhibitor to Daily Living 8
Slide 9: VRT is the only FDA cleared therapy for vision restoration
• VRT is the only FDA cleared therapy (510k) for restoration of vision loss from neurological damage • A light based prescription stimulation therapy – “at home” • Clinically proven to restore lost vision • 20 clinical studies/papers approximately 70% of patients benefit • Substantial IP portfolio:
Slide 10: Patient testimonial and impact on visual field
“My vision began coming back after the first month of therapy…I passed my driving test, can read normally, and enjoy driving my boat on the lake…my life is back to normal.” – Stroke survivor and VRT patient Pre-VRT Post-VRT Illustration of the Impact of the Improvement in a Patient’s Visual Field an
Slide 11: Scalable business model, development work now complete
Ensure broad benefit from NovaVision therapies and not only 70% from VRT Drive down cost of delivery inherent with “hardware centric” business model and processing costs to largely remove pricing barriers Create a scalable business model capable of addressing the size of the mark Prototypes hi
Slide 12: NeuroEyeCoach complements VRT
• Broaden benefit to all patients not only 70% provided by VRT through the introduction of new therapy in patients overall therapy regime • Scientific Advisory Board recommended introduction of saccadic eye training program to complement VRT: Scientifically supported to benefit patients Previous
Slide 13: Professional NeuroEyeCoach models and trials
• Significant Physician and Rehab Center interest led to the development of two new Professional NeuroEyeCoach models: Both programs now complete Professional Center Program being trialed in largest rehab center in US NovaVision has already commenced a three-center patient trial for NeuroEyeCo
Slide 14: Web-delivered VRT and therapy suite commercially available 2015
• Web deliverable VRT development now completed • Therapy suite of VRT and NEC commercially available first quarter 2015 Broader benefit to patients Web delivery ensures scalability Elimination of previously required hardware enables significant reduction in pricing: (~$3,000 today for VRT to
Slide 15: HealthSouth rehabilitation network approval
NovaVision has received approval from HealthSouth to make available its VRT diagnostic to its 100+ hospital network, following a trial • Most Stroke patients visit a rehabilitation center at some point in time • Diagnostic component already part of VRT • Rehab center derives financial benefit and im
Slide 16: Neurosurgeon quote on deep brain access
“It is the ideal system for providing deep brain access through a smaller incision.” -Neurosurgeon Quote 16
Slide 17: VBAS vs old blade/ribbon retractor technology
Old Blade/Ribbon Retractor Technology Evenly disperses and reduces pressure More accurate target access, no target shifting Superior field of view, clear working channel VBAS Next Generation Technology Less invasive: requires smaller opening IGS and inter-operative MRI compatible No repo
Slide 18: VBAS offers savings for hospitals
Surgeon Discussions Indicate that VBAS Offers Savings for Hospitals: Surgeon feedback indicates that VBAS can reduce the operating time Shorten discharge times Reduced use of consumables during Operation = Potential Savings of Thousands of Dollars Per Procedure 18
Slide 19: Previously inoperable, now operable
Previously Inoperable…Now Operable “Her case would have been inoperable via a traditional surgery, because she was taking Avastin®, which delays surgical wound healing. The VBAS’ minimally invasive nature enabled the surgeon to gain access to the target through only a 3cm incision. The patient was d
Slide 20: Management's 4 pronged strategy
Drive US Market Penetration Increase Focus on International Expansion Secure More Clinical and Scientific Data Focus on New Product Development Management’s 4 Pronged Strategy to Drive Revenue and Shareholder Value 20
Slide 21: Progress year to date: US market
Progress Year to Date: • Well defined target market of 3,500 neurosurgeons being aggressively marketed to directly with clinical data • VBAS continues to gain traction with neurosurgeons: VBAS approved in 23 hospitals year to date bringing total to >170 • Strong pipeline of hospitals going through t
Slide 22: Progress year to date: international markets
Progress Year to Date: • Systematic focus on International Markets • Target countries where it has patent protection and/or clear regulatory path • Utilize distributors with experience in neurosurgical devices • Entered into distribution or evaluation agreements with Brazil, France, India, Russia, S
Slide 23: Progress year to date: clinical and academic support
Progress Year to Date: • Strong Support from leading neurosurgeons at Weill Cornell Medical Center: Submitted two peer reviewed papers using Vycor’s VBAS bringing total to 7 peer reviewed/published studies Presented their work with the VBAS in Xian China, Prague, Paris and most recently the CNS
Slide 24: Progress year to date: new VBAS devices
Progress Year to Date: • Two smaller VBAS devices now going through manufacturing process in Asia • Finalization of design and testing on New IGS compatible devices. Co Marketing and Co Promotion Agreement being explored. Broad compatibility strategy being adopted. IGS Design IGS Prototype 24
Slide 25: Publicly Traded on OTCQB, VYCO
Publicly Traded on OTCQB, VYCO Current share price (11/24/14) $2.18 Shares Ent. Value (1) Common 10.9m $21.6m Common and Preferred 12.0m $24.0m Fully diluted (for options and warrants) 17.9m $27.7m Cash Balance 9/30/14 $2.5m Operating Cash Burn Q1-3 2014 (2) $1.1m (1) Enterprise Value is market cap
Slide 26: Management Presenting and Websites
Management Presenting Our Websites Peter Zachariou - Chief Executive Officer David Cantor- President www.vycormedical.com Corporate Headquarters 6401 Congress Avenue Suite 140 www.vycorvbas.com Boca Raton, FL. 33487 www.novavision.com German Office www.novavisionvrt.com Klausenerstr. 12 www.neuroeye
Slide 27: Supplemental Group Information
Supplemental Group Information 27
Slide 28: Management team
Name Title Experience CEO & Extensive operating experience over range of manufacturing businesses Peter Director Active investor in variety of companies and industries, both public and private, Zachariou specializing in capital formation/raising and development companies 22 years experience of
Slide 29: Advisors and affiliations
Name Experience and Affiliations Dr David Langer Director of Cerebrovascular Neurosurgery at St. Luke’s-Roosevelt, Beth-Israel and Long Vycor Island College Hospitals (New York, NY) Dr Konstantin Slavin University of Illinois at Chicago (Chicago, IL); Alexian Neuroscience Center (Elk Grove Vycor
Slide 30: Exact Mechanism of Neuroplasticity is Not Known
Exact Mechanism of Neuroplasticity is Not Known: • Each 1mm² of a nerve bundle carries up to 1 million nerve fibers • Brain injury often affects an extensive network of connectivity • Some networks in the brain are duplicated and some are not • Improvements are probably related to “extensive redunda
Vycor Medical — Investor Presentation (December 2014) on 6ix